Form 4: Adverum Biotechnologies COO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, sold shares of common stock on May 15, 2025, to satisfy tax obligations related to vesting performance stock units.
Summary
- On May 15, 2025, Peter Soparkar, the Chief Operating Officer of Adverum Biotechnologies, sold 2,960 shares of common stock.
- The sale was executed to cover tax obligations arising from the vesting and settlement of performance stock units.
- The shares were sold at prices ranging from $1.9701 to $2.01, with a weighted-average sale price of $2.
- Following the transaction, Soparkar still beneficially owns 39,154 shares of Adverum Biotechnologies common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (stock sale for tax obligations) and doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation and are not necessarily indicative of the executive's view of the company's prospects.
Stakeholder Impact
- The sale has a minimal impact on shareholders as it is a small percentage of the outstanding shares and is related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of stock sale transaction. |
| 05/16/2025 | Date of signature on the Form 4 filing. |
Keywords
Adverum Biotechnologies, Peter Soparkar, stock sale, Form 4, tax obligations, performance stock units, ADVM, COO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.